Canakinumab to reduce deterioration of cardiac and respiratory function in SARS-CoV-2 associated myocardial injury with heightened inflammation (canakinumab in Covid-19 cardiac injury: The three C study).

Calvin C ShengDebasis SahooSiddharth DugarRobier Aguillon PradaTom Kai Ming WangOssama K Abou HassanDanielle BrennanDaniel A CulverPrabalini RajendramAbhijit DuggalA Michael LincoffSteven E NissenVenu MenonPaul C Cremer

Published in: Clinical cardiology (2020)

The three C study will provide insights regarding whether IL-1β inhibition may improve outcomes in patients with SARS-CoV2 associated myocardial injury and increased inflammation.

Keyphrases

sars cov
oxidative stress
respiratory syndrome coronavirus
coronavirus disease
heart failure
insulin resistance